Structural juxtaposition of the 3,4,5-trimethoxyphenyl group in the same molecule with a piperazine or homopiperazine ring has been realized in a series of mescaline analogues (I-IV) as part of an investigation into the pharmacological properties of the seven-membered perhydro-1,4-diazepines (homopiperazines). The analogous six-membered piperazines were synthesized and tested as reference substances to determine whether the seven-membered ring conveyed special properties. A variety of pharmacological tests of action on the CNS showed that replacement of the amino group in mescaline by the heterocycles significantly alters the biological activity. In particular, both the piperazine and the homopiperazine derivatives displayed sedative activity to about the same extent.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.2600720324DOI Listing

Publication Analysis

Top Keywords

piperazine homopiperazine
12
mescaline analogues
8
synthesis action
4
action central
4
central nervous
4
nervous system
4
system mescaline
4
analogues piperazine
4
homopiperazine rings
4
rings structural
4

Similar Publications

Background: Glaucoma is a leading cause of blindness, affecting retinal ganglion cells (RGCs) and their axons. By 2040, it is likely to affect 110 million people. Neuroinflammation, specifically through the release of proinflammatory cytokines by M1 microglial cells, plays a crucial role in glaucoma progression.

View Article and Find Full Text PDF
Article Synopsis
  • Modifications to the structure of betulinic acid included adding two acetyloxy groups, aiming to increase the compounds' ability to kill cancer cells.
  • The tested compounds showed high cytotoxicity against ovarian carcinoma cells, particularly the derivatives with rhodamine B and rhodamine 101, which also displayed selectivity toward cancer cells over normal fibroblasts and led to cell cycle arrest in the G1/G0 phase, indicating effects like necrosis and apoptosis.
View Article and Find Full Text PDF

The innovative synthesis of 3,8-dibromo-2,9-dinitro-5,6-dihydrodiimidazo [1,2-a:2',1'-c]pyrazine and 3,9-dibromo-2,10-dinitro-6,7-dihydro-5-diimidazo [1,2-a:2',1'-c][1,4]diazepine is described in this study. The tricyclic fused molecular structures are formed by the respective amalgamation of piperazine and homopiperazine with the imidazole ring containing nitro. Compound and possess excellent high-density physical properties (ρ = 2.

View Article and Find Full Text PDF

Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile.

J Med Chem

January 2024

Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.

Atypical dopamine transporter (DAT) inhibitors have shown therapeutic potential in the preclinical models of psychostimulant use disorders (PSUD). In rats, 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)-piperazin-1-yl)-propan-2-ol () was effective in reducing the reinforcing effects of both cocaine and methamphetamine but did not exhibit psychostimulant behaviors itself. Improvements in DAT affinity and metabolic stability were desirable for discovering pipeline drug candidates.

View Article and Find Full Text PDF

Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2.

J Agric Food Chem

September 2022

Syngenta Crop Protection Research, Schaffhauserstrasse, CH-4332 Stein, Switzerland.

Applications of piperazine and homopiperazine in drug design are well-established, and these heterocycles have found use as both scaffolding and terminal elements and also as a means of introducing a water-solubilizing element into a molecule. In the accompanying review (10.1021/acs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!